Repository logo
  • English
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • Research Outputs
  • Fundings & Projects
  • People
  • Statistics
  • English
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Institute of Global Health Equity Research
  3. Prof. Daniel Seifu
  4. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa
 
  • Details
Options

Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa

Journal
BMC Women's Health
ISSN
1472-6874
Date Issued
2018-02-14
Author(s)
Endale Hadgu
Daniel Seifu
Wondemagegnhu Tigneh
Yonas Bokretsion
Abebe Bekele
Markos Abebe
Thomas Sollie
Sofia D. Merajver
Christina Karlsson
Mats G. Karlsson
DOI
https://doi.org/10.1186/s12905-018-0531-2
Abstract
Background
Breast cancer is a heterogeneous disease with several morphological and molecular subtypes. Widely accepted molecular classification system uses assessment of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki67. Few studies have been conducted on the incidence and molecular types of breast cancer in Sub-Saharan Africa. Previous studies mainly from Western and Central Africa, showed breast cancer to occur at younger ages and to present with aggressive features, such as high-grade, advanced stage and triple-negative phenotype (negative for ER, PR and HER2). Limited data from East Africa including Ethiopia however shows hormone receptor negative tumors to account for a lower proportion of all breast cancers than has been reported from elsewhere in Africa.

Methods
In this study from Tikur Anbessa Specialized Hospital, 114 breast cancer patients diagnosed between 2012 and 2015 were enrolled. ER, PR, Ki67 and HER2 receptor status were assessed using immunohistochemistry from tissue microarrays. FISH was used for assessment of gene amplification in all equivocal tumor samples and for confirmation in HER2-enriched cases.

Results
The distribution of molecular subtypes was: Luminal A: 40%; Luminal B: 26%; HER2-enriched: 10%; TNBC: 23%. ER were positive in 65% of all tumors and 43% the cases were positive for PR. There was statistically significant difference in median age at diagnosis between the molecular subtypes (P < 0.05). There was a bimodal distribution of molecular subtypes in different age ranges with Luminal B subtype being more common at younger ages (median = 36) and Luminal A subtype more prevalent at older ages (median = 42). There were no statistically significant differences in tumor grade, histology, and stage between the molecular subtypes of breast cancer.

Conclusion
The present study detected Luminal A breast cancer to be the most common subtype and reveals a relatively low rate of hormone receptor negative and TNBC. Our findings and results from other East African studies suggest geographic variability in the distribution of the molecular subtypes of breast cancer in Africa and hence have important clinical and policy implications for breast cancer control and treatment in Ethiopia.
File(s)
No Thumbnail Available
Name

s12905-018-0531-2.pdf

Size

475.8 KB

Format

Adobe PDF

Checksum

(MD5):4c79673affdf107d0d14642335677892

  • logo.footer.image.logo
  • grid-colum.footer.image.logo
Rwanda:

Office Hours: 8:00 a.m. - 5:00 p.m.
p: 0786.405.072
Kigali Heights, Plot 772
KG 7 Ave., 5th Floor
PO Box 6955
Kigali

United States:

Office Hours: 9:00 a.m. - 5:00 p.m.
800 Boylston Street, Suite 300
Boston, MA 02199

Connect with us:

View our privacy policy.

If you are interested in working for the university, please visit our job board for open positions.

To get in touch with UGHE, please send us an email.

Copyright © 2024, UGHE.org All Rights Reserved

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback